NCT04157569 CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia
| NCT ID | NCT04157569 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Navy General Hospital, Beijing |
| Condition | Acute Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2019-11-05 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2019-11-05 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Male * not pregnant female * patients \>=60 years old * Diagnosis of acute leukemia Exclusion Criteria: * Pregnancy * HIV positive * patients \>=100 years old
Contact & Investigator
Liren Qian, MD
STUDY CHAIR
Navy General Hospital, Beijing
Frequently Asked Questions
Who can join the NCT04157569 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 100 Years, studying Acute Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04157569 currently recruiting?
Yes, NCT04157569 is actively recruiting participants. Contact the research team at qlr2007@126.com for enrollment information.
Where is the NCT04157569 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04157569 clinical trial?
NCT04157569 is sponsored by Navy General Hospital, Beijing. The principal investigator is Liren Qian, MD at Navy General Hospital, Beijing. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.